The diagnostic and prognostic role of plasminogen activator inhibitor-1 (PAI-1) in hospitalized patients with pneumonias of different etiologies

ABSTRACT

Aim: to estimate the diagnostic and prognostic role of PAI-1 on admission in hospitalized patients with confirmed COVID-19 pneumonia, comparing with bacterial pneumonia. Material(s) and Method(s) We observed 3 groups Main (1) - 85 patients (59 (52;65) years, men - 45 (52.9%)), hospitalized with COVID-19 pneumonia (40 patients with moderate, 25 patients with severe, 20 patients with critical);Comparative (2) - 55 patients (48.9 (34;62) years, men - 30 (54.5%)), hospitalized with communityacquired pneumonia of bacterial etiology (CABP) without COVID-19;Control (3) - 25 healthy volunteers (50.0 (35;65) years, men - 13 (52.0%)). General tests, plasma level of PAI-1 (ELISA Kit, Elabscience) before starting of anticoagulants, statistic. Result(s) The highest level of PAI-1 (6.1 [0.15;18] ng/ml) was in Main group and exceeds the Control group (0.1 [0.09;0.11] ng/ml), p1-3=0,000) in more than 60 times. PAI-1 in CABP didn't differ from Control group (Fig.1) The highest levels of PAI-1 at admission had patients with severe and critical course of COVID-19. Conclusion(s) 1) significantly increase of PAI-1 in COVID-19 pneumonia demonstrates the cornerstone in thrombogenesis of this disease - problems in fibrinolysis system, which is the main difference between CABP;2) PAI-1 is associated with COVID-19 severity and could be the crucial marker for patients' distribution. (Figure Presented).